Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results

Joel E. Gallant, Ellen Koenig, Jaime F. Andrade-Villanueva, Ploenchan Chetchotisakd, Edwin DeJesus, Francisco Antunes, Keikawus Arastéh, Giuliano Rizzardini, Jan Fehr, Hui C. Liu, Michael E. Abram, Huyen Cao, Javier Szwarcberg

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity. Methods: International, randomized double-blind active-controlled trial to evaluate the efficacy and safety of COBI vs ritonavir (RTV) as a pharmacoenhancer of atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate in HIV treatment-naive patients followed through week 144. Results: At Week 144, virologic suppression was achieved in 72% (COBI) and 74% (RTV) of patients. Adverse events leading to study drug discontinuation occurred in 11% of patients in each group. Median changes in serum creatinine (mg/dL) were +0.13 (COBI) and +0.07 (RTV) and were unchanged from week 48. Conclusions: Once-daily COBI is a safe and effective pharmacoenhancer of the protease inhibitor atazanavir.

Original languageEnglish (US)
Pages (from-to)338-340
Number of pages3
JournalJournal of Acquired Immune Deficiency Syndromes
Volume69
Issue number3
DOIs
StatePublished - Jul 1 2015
Externally publishedYes

Keywords

  • Antiretroviral
  • clinical trial
  • Cobicistat
  • HIV
  • pharmacoenhancer

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Medicine(all)

Fingerprint

Dive into the research topics of 'Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results'. Together they form a unique fingerprint.

Cite this